Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine for Cognitive Deficits in Neurofibromatosis Type 1 (NF1-EXCEL)
NCT02256124Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Oct 2014
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of lamotrigine in neurofibromatosis type 1 (NF1), sponsored by Erasmus MC. Primary endpoint: Performance Intelligence Quotient at 26 weeks. Started Oct 2014; status: terminated.
02
Drugs
lamotrigine
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT02256124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256124.